# Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

> **NCT00866242** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 20 (actual)

## Conditions studied

- Shigella

## Interventions

- **BIOLOGICAL:** CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a

## Key facts

- **NCT ID:** NCT00866242
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Reactogenicity met study halting criteria
- **Last updated:** 2021-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866242, "Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00866242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*